Cost-effective pharmacologic therapies to treat chronic hepatitis B: how far have we really come?
Holbrook
Michelle L
ML
Highmark Blue Shield, 120 Fifth Ave., Pittsburgh, PA 15222. USA. michelle.holbrook@highmark.com
D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D006147:Guanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006513:Hepatitis B e Antigens / Q000276:immunology; D006515:Hepatitis B virus / Q000187:drug effects / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D014481:United States
D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D019259:Lamivudine; C413685:entecavir; D006147:Guanine